期刊
CANCER CELL
卷 21, 期 3, 页码 333-347出版社
CELL PRESS
DOI: 10.1016/j.ccr.2012.01.010
关键词
-
资金
- Canadian Cancer Society Research Institute [018355]
- Terry Fox Foundation
- CIHR Institute of Cancer [TFF 105265]
- National Cancer Institute (NIH) [K08CA138764]
- Paul Nabil Bustany Fund for Synovial Sarcoma Research
- Arthritis Society
Synovial sarcoma is a translocation-associated sarcoma where the underlying chromosomal event generates SS18-SSX fusion transcripts. In vitro and in vivo studies have shown that the SS18-SSX fusion oncoprotein is both necessary and sufficient to support tumorigenesis; however, its mechanism of action remains poorly defined. We have purified a core SS18-SSX complex and discovered that SS18-SSX serves as a bridge between activating transcription factor 2 (ATF2) and transducin-like enhancer of split 1 (TLE1), resulting in repression of ATF2 target genes. Disruption of these components by siRNA knockdown or treatment with HDAC inhibitors rescues target gene expression, leading to growth suppression and apoptosis. Together, these studies define a fundamental role for aberrant ATF2 transcriptional dysregulation in the etiology of synovial sarcoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据